spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Merck Introduces Parteck® COAT Excipient, a Fast-Dissolving Material for Immediate Release Coating

Merck


• Designed to simplify the formulation and coating process for tablets
• Optimized particle size leads to fast dissolving and increases coating process efficiency

Merck has launched its Parteck® COAT excipient, a new functional material designed for immediate release film coating applications. Parteck® COAT is a particle engineered polyvinyl alcohol (PVA) with a unique particle structure that enables rapid dissolution even at low temperatures leading to an increased process efficiency.

Merck is the only supplier to offer a fast-dissolving PVA for coating applications. The water-soluble particle offers reliable batch-to-batch consistency, contributing to the quality and performance of the final drug product.

Parteck® COAT offers low viscosity in solution, even at high concentrations of 20 percent, leading to higher efficacy. Compared with existing PVAs for coating applications, Parteck® COAT has the potential to double the polymer concentration and cut the process time in half along with the following advantages:
• A stable moisture barrier to improve stability of moisture-sensitive drug substances.
• Excellent surface finishing to increase the value of drug formulations.
• A high concentration of spraying liquid to increase coating efficacy.

Parteck® COAT is compliant with and surpasses the requirements of all major pharmacopoeias, including United States Pharmacopoeia (USP), European Pharmacopoeia (Ph. Eur.), Chinese Pharmacopoeia (ChP) and Japanese Pharmaceutical Excipients (JPE).

The new excipient will be incorporated into Merck’s Emprove® program. This program provides customers instant, online access to regulatory and technical information about the excipient and more than 400 other chemicals, as well as filters and single-use components to facilitate risk assessment and qualification processes.

Experts from Merck will be available at booth #1037 at the American Association of Pharmaceutical Scientists’ PharmSci 360 conference in San Antonio, Texas to discuss Parteck® COAT and the entire Emprove® portfolio.
phone +33 (0)5 57 960 960
email Sebastien.ribault@merckgroup.com
web www.merckmillipore.com/adaptive-CDMO
email 1 rue Jacques Monod, Site Montesquieu, 33650 Martillac, France
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Regulatory bottlenecks mean EU clinicians and patients could lose access to medical devices under new rules

European clinicians and their patients could lose access to vital medical devices, including in-vitro diagnostics, due to a lack of agencies able to certify products in time to comply with strict new regulations.
More info >>


White Papers

Mouse Models for Evaluation of Vaccines and Therapeutics Against Staphylococcal Infections

IBT Bioservices

Introduction Staphylococcus aureus (SA) is a ubiquitous, formidable Gram-positive pathogen associated with skin and soft tissue, as well as lifethreatening systemic infections. SA is a leading cause of hospital- and community-associated infections worldwide, affecting humans and animals. The wide range of pathologies reflects the diverse abilities of this microbe to escape the innate and adaptive immune response using virulence factors. Since its first emergence in the 1960s methicillin-resistant SA (MRSA) has become endemic in hospitals and healthcare settings worldwide. In the 1990s, community associated MRSA strains (CA-MRSA) emerged, and are spreading worldwide posing a major global challenge.
More info >>

Industry Events

Clinical Trials Europe | Partnerships, Outsourcing, Operations & Technology

27 August - 21 November 2019, Barcelona, Spain

On 19-21 November 2019, the clinical trial community's most influential stakeholders will be meeting in Barcelona to discuss the evolving landscape, honing in on what it takes to harness true value from partnerships, outsourcing, operations, technology and early clinical development, for a faster, more efficient route to market.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement